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E-mail address: Sanjaya.Kuruppu@monash.edu (S.Endothelin Converting Enzyme-1 (ECE-1) plays a signiﬁcant role in the regulation of vascular tone
and hence blood pressure. It has also been implicated in the pathogenesis of cardiovascular diseases,
female malignancies and Alzheimer’s disease. Four different isoforms of ECE-1 exist and have vary-
ing degrees of distribution throughout the cell. Production of ET-1 by ECE-1 occurs at the cell surface
and the expression and localisation of ECE-1 is the rate limiting step in the production of ET-1. This
review looks at the current knowledge on ECE-1 phosphorylation and other stimuli which act
induce trafﬁcking of ECE-1 to the cell surface.
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Endothelins are highly potent vasoconstrictors which regulate
vascular tone and blood pressure. Three isoforms of endothelin
(ET-1, ET-2 and ET-3) have been identiﬁed, with each one encoded
by a different gene. Each isoform is composed of 21 amino acids,
however ET-1 is the most abundant and hence the most physiolog-
ically relevant.
Endothelin is produced by the cleavage of its precursor big
endothelin (BigET), which is a 38 amino acid peptide with no
known biological functions. BigET is cleaved by the highly speciﬁc
metalloprotease Endothelin Converting Enzyme-1 (ECE-1) be-
tween Trp21 and Val22 to produce the 21 amino acid bioactive
endothelin. This makes the expression and localisation of ECE-1;
should read ECE-1 the rate limiting step in the production of endo-
thelin. Cloning studies have shown ECE-1 to be a type II membrane
bound metalloprotease which exists as a dimer on the cell surface.
The amino acid sequence of ECE-1 includes a zinc co-ordinating
motif (HEXXH) and shows signiﬁcant homology (40%) with human
neutral endopeptidase [1]. A single gene encodes four different iso-
forms of ECE-1 (ECE-1a, 1b, 1c & 1d), each one under the control of
different promoters (Table 1). The large extracellular domain ofevier B V on behalf of Federation. .
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Kuruppu).ECE-1 is responsible for catalytic activity, and the only difference
amongst the four isoforms lie in the cytoplasmic N-terminal re-
gion. Subtle differences in the amino acid sequence of the N-termi-
nus play an important role in the different sub cellular trafﬁcking
of ECE-1 [2,3].
In addition to the production of endothelin and thus its role in
regulating vascular tone, ECE-1 has been implicated in a range of
other pathological and physiological functions. ETs and hence
ECE play a role in endocrine function as well as growth and devel-
opment. ECE-1 has also been implicated in the pathogenesis of a
range of disease states including cancer [4], cardiovascular diseases
[5–7] and Alzheimer’s disease [8–10]. Hence it has been the focus
of intense research and is itself a validated drug target. Given that
the production of ET-1 by ECE-1 occurs at the cell surface, trafﬁck-
ing of ECE-1 to the cell surface is an important cellular process that
has attracted the attention of researchers. ECE-1 trafﬁcking can be
stimulated by physiological and pathophysiological stimuli and ap-
pears to involve a Protein Kinase dependant pathway [11]. In this
review, we discuss the effects of ECE-1 phosphorylation and some
of the stimuli that induce phosphorylation/trafﬁcking.
1.1. Phosphorylation of ECE-1
Phosphorylation has widely been accepted as a process by
which localisation and activity of many cellular enzymes are
regulated. To date most studies examining the phosphorylation
of ECE-1 and its downstream effects have largely been conducted
on endothelial cells, while one study has used ECE-1 transfectedof European Biochemical society.Open access under CC BY-NC-ND license.
Table 1
Isoforms of ECE-1 along with their predictive phosphorylation sites, amino acid length and constitutive localisation.
Putative phosphorylation site(s) for Protein Kinase C, MAP Kinase and casein kinase II are indicated by an ⁄, bold and underlined and a ^ respectively.
The conserved sequence leading to the transmembrane domain is indicated as TM.
a[15].
b[16].
c[3,12].
Fig. 1. Trafﬁcking of ECE-1a and c isoforms in endothelial cells in response to PMA
(PKC activator) and high glucose environment respectively. A high glucose
environment results in the phosphorylation of ECE-1c which is then trafﬁcked to
the cell surface. Activation of PKC by PMA results in increased ECE-1a expression,
however it is not known if this also leads to increased trafﬁcking to the cell surface
via a phosphorylation dependant mechanism.
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making it difﬁcult to identify which speciﬁc isoform(s) are effected
by phosphorylation without isoform speciﬁc probes such as
antisera.
The control of ECE-1 expression by Protein Kinases was ﬁrst re-
ported by Uchida et al. (in 1997) in which the ECE-1 expression in
bovine glomerular endothelial cells (which constitutively express
ECE-1) was examined [11]. These cells produce ET-1 which in turn
acts to promote contraction of the nearby mesangial cells, thereby
regulating vascular tone and hence glomerular ﬁltration rate. This
study used inhibitors of PKA, C and G along with a ribonuclease
protection assay to prove the involvement of these respective ki-
nases in ECE-1 expression [11]. Furthermore, the PKC activator
12-O-tetradecanocyl-phorbol-13-acetate (TPA) increased ECE-1
mRNA and protein expression in a concentration dependant man-
ner over 4 h [11]. The authors argue that the reduced ECE-1 expres-sion observed over 24 h of TPA treatment was a consequence of
PKC depletion.
E-twenty-six (ETS) family constitute a large family of transcrip-
tion activators that bind DNA sequences containing the core motif
GGA/T. The transcriptional activator Ets-1 is known to induce the
expression of ECE-1a isoform [13]. Activation of PKC by the phorbol
ester PMA in EA.hy926 cells has shown to increase the levels of
both Ets-1 and ECE-1a mRNA [13,14] (Fig 1). This activity was
shown to be sensitive to inhibitors that partially blocked induction
of Ets-1 mRNA, providing initial evidence for the regulation of ECE-
1 expression through phosphorylation [14].
Further studies on ECE-1 phosphorylation conﬁrmed that all
ECE-1 isoforms (except ECE-1a) are constitutively phosphorylated
and have a number of phosphorylation consensus sequences
[15]. These studies used human umbilical cord endothelial cells
(HUVECs) to identify Ser18 and Ser20 (according to ECE-1c number-
ing) as constitutively phosphorylated residues in ECE-1b, c and d
(Table 1). ECE-1a being the most divergent of all ECE-1 isoforms
was lacking in these residues and is therefore not constitutively
phosphorylated [15]. In vitro studies conducted suggest that ECE-
1 phopshorylation is mediated by CK-I or a CK-like kinase [15].
32P labelling studies of ECE-1a indicate the possible presence of
other phorphorylation sites on ECE-1 isoforms which has since
been conﬁrmed in subsequent studies [16].
Phosphorylation is an important mechanism that can regulate
the enzyme activity directly or indirectly, and govern the sub cellu-
lar trafﬁcking of the enzyme thereby effecting substrate speciﬁcity
[15]. The pH optimum of the enzyme is substrate dependant with
small peptide substrates such as bradykinin and substance P having
a pH optimumof 5.6–5.8while bigET has a pH optimumof 7. There-
fore when ECE-1 is localised to different sub cellular compartments
where the internal pH values differ signiﬁcantly, it is likely to opti-
mally cleave different substrates. This in turn suggests different
functions for ECE-1 depending on its localisation [17].
The relevance of phosphorylation to ECE-1 sub cellular localisa-
tion was further examined by Jafri and Ergul using CHO cells trans-
fected with ECE-1a and 1b [12]. In CHO cells, these ECE-1 isoforms
internalised in response to PKC mediated phosphorylation. Similar
results were observed in relation to PKA mediated phosphorylation
of ECE-1b, but not ECE-1a due to its lack of PKA phosphorylation
Fig. 2. Trafﬁcking of ECE-1 in CHO cells transfected with ECE-1a and b in response to PMA (PKC activator) and forskolin (PKA activator). PMA mediated phosphorylation of
ECE-1a and c result in the internalisation and trafﬁcking to the cell surface respectively. PKA mediated phosphorylation of ECE-1b results in its internalisation.
2214 S. Kuruppu, A.I. Smith / FEBS Letters 586 (2012) 2212–2217sites (Fig 2) [12]. Unpublished studies conducted in our lab using
CHO cells transfected with ECE-1c suggest that PMA mediated
phosphorylation induces the trafﬁcking of ECE-1c to the cell sur-
face (Tochon-Danguy, unpublished work; Fig 2). This observation
is supported by parallel studies conducted on endothelial cells
(see below) where only phosphorylation and the subsequent traf-
ﬁcking to the cell surface of only ECE-1c was observed in response
to high glucose[18]. Although ECE-1a expression increases in re-
sponse to PMA, whether this reﬂects increased trafﬁcking to the
cell surface was not determined by the authors [14] (Fig 1).
Phosphorylation of ECE-1 upon PKC activation was conﬁrmed
by our group [16]. PMA increased ECE-1 phosphorylation between
50% and 100% of basal levels. In addition, our data [16] indicate
both basal and stimulated phosphorylation of ECE-1 by PKC, which
was sensitive to the PKC inhibitor bisindolylmaleimide (BIM).
Using live Ea.hy926 cells, we have also shown that stimulation of
PKC activity by PMA increases the cell surface activity of ECE-1,
suggesting the trafﬁcking of the enzyme to the cell surface in re-
sponse to phosphorylation [16]. This was conﬁrmed by subsequent
studies in which PMA stimulation only increased ECE-1 activity of
cell membrane preparations [19]. This study only focused on total
ECE-1 activity and not the speciﬁc isoforms of ECE-1. However, this
observation suggests that the overall trafﬁcking of ECE-1c isoform
to the cell surface compensates for the internalisation of ECE-1b,
and perhaps ECE-1a. There are no published studies examining
the effect on ECE-1d upon Protein Kinase activation.
ECE-1 is known to play a key role in the growth of several can-
cers. Previous studies have focused on the comparison of ECE-1
expression levels in breast cancer with normal tissue [20], and
the effects of ECE-1 inhibition on tumour cell viability & invasive-
ness [21]. An in depth study conducted using prostate cancer cells
revealed the opposing effects of ECE-1a and ECE-1c in a prostate
cancer cell line [22]. ECE-1c was found to have tumour promoting
effects while ECE-1a over expression showed anti proliferative and
anti invasive effects. Furthermore, conditioned media from ECE-1a
over expressing cells reduced the invasiveness of ECE-1c over
expressing tumour cells [22]. The authors argue that the presence
of a soluble form of ECE-1a in the culture media may account for
this observation. However, studies conducted by us indicate that
soluble ECE-1 in culture media is the result of a proteolytic cleav-
age event which only releases the catalytically active C-terminal
region into the media [19]. Given that the only difference amongst
the isoforms of ECE-1 lie in the N-terminal cytoplasmic region, it is
likely that the anti proliferative effects are attributed to a second
messenger pathway speciﬁcally activated by the N-terminal region
of ECE-1a. This is further supported by other studies which usedglioblastoma cells. Addition of exogenous ET-1 only partially re-
stored the tumour promoting effects of ECE-1c [23]. Future studies
on the anti proliferative effects of ECE-1a should examine the po-
tential of ECE-1a phosphorylation to act as a stimulus which acti-
vates the anti proliferative pathway.
Efforts have been made to examine speciﬁc physiological/path-
ophysiological stimuli that may activate ECE-1 trafﬁcking.
Although the expression of various ECE-1 isoforms were not exam-
ined at the protein level due to the lack of isoform speciﬁc anti
bodies, many investigators have overcome this problem by focus-
ing only on the determination of isoform speciﬁc mRNA levels. This
approach however does not allow the determination of speciﬁc iso-
forms that may be trafﬁcked to the cell surface or internalised in
response to these stimuli which include ET-1 [24], hyperglycaemia
[18,25], hypercholesterolemia [26], shear stress [27] as well as var-
ious pharmacological interventions [28].
1.2. Factors effecting ECE-1 expression
1.2.1. Et-1
Given that one of the main functions of ECE-1 is the production
of ET-1, the presence of a negative feedback loop to regulate ECE-1
expression would seem logical. This hypothesis was tested by Nao-
mi et al. in 1998 [24] using the SV40-transformed rat vascular
endothelial cell line TRLEC-03. Treatment of cells with ET-1 re-
sulted in a drop in ECE-1 mRNA and protein expression over 6 h.
ET-1 acts on ET-B and A receptors which are located on the surface
of endothelial cells or both endothelial and vascular smooth mus-
cle cells respectively [24]. Prior incubation of cells with the ET-B
receptor antagonist BQ788 prevented the ET-1 induced decrease
in ECE-1 expression. This effect was not observed in the presence
of ET-A receptor antagonist BQ-123, conﬁrming the involvement
of ET-B receptors in ET-1 mediated reduction in ECE-1 expression
[24]. The ET-B receptor is associated with phospholipase C and
hence an inﬂux of Calcium ions occurs in response to ET-B receptor
activation [29]. The treatment of these cells with the Calcium ion-
ophore ionomycin, replicated the effects of ET-1 on ECE-1 expres-
sion. This ﬁnding conﬁrms that inﬂux of Calcium through the
action of ET-B receptor is the mechanism behind ET-1 mediated
reduction in ECE-1 expression in TRLEC-03 cells [24].
1.2.2. Shear stress
Mechanical force exerted on endothelial cells by the ﬂow of
blood through vessels is referred to as shear stress [30]. It is one
of the main factors governing the endothelium dependant changes
in vascular tone [31,32]. Endothelial cells can sense shear stress
Fig. 3. Both nLDL and oxLDL promotes the production of ET-1 via an increase in
ECE-1 expression. ET-1 in turn increases ROS thereby converting nLDL to oxLDL for
uptake into endothelial cells via the LOX-1 receptor. This completes a vicious cycle
involving nLDL, ET-1, ROS and oxLDL.
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in turn controls vascular tone [27].
A cell culture model in which HUVECs were exposed to increas-
ing levels of laminar shear stress has been used in an effort to iden-
tify the changes in shear stress induced ECE-1 expression [27,30].
Results indicate that mRNA levels of both ECE-1a and b isoforms
are down regulated in response to long term arterial levels of shear
stress accompanied by a reduction in ET-1 synthesis [30]. The ef-
fect of shear stress on the isoforms of ECE-1 expressed on the cell
surface, and thus directly in contact with the blood vessel lumen
was not examined in this study. However, the authors argue that
the expression of ECE-1 on the cell surface in response to shear
stress is a likely mechanism by which endothelial cells adapt to
changes in blood ﬂow [30]. These results were reproduced by Mas-
atsuga et al. in 2003 using both HUVEC and bovine aortic endothe-
lial cells (BAEC), thereby indicating the species independence in
shear stress induced ECE-1 down regulation, which was time and
intensity dependant [27]. Shear stress increased levels of reactive
oxygen species (ROS) and was also shown to occur in BAECs [27].
The effect of increased ROS was examined by using H2O2 which
down regulated ECE-1 expression, an effect shown to be sensitive
to the antioxidant N-acetyl cystein (NAC). Shear stress induced
reduction in ECE-1 expression was also found to be sensitive to
NAC implicating an oxidative stress induced mechanism for the
reduction of ECE-1 expression [27].
1.2.3. Hypercholesterolemia
This is a crucial risk factor for the formation of atherosclerotic
plaques [33]. Increased levels of native high density lipoproteins
(nLDL) promote the inﬂux of lipoproteins into the intimal layer
of blood vessels, thus triggering the formation of plaque [34].
This process can be further promoted locally by ROS which can
modify the nLDL to oxidised LDL (oxLDL) [34]. ECE-1 levels are
elevated in the ﬁbrous capsule of atherosclerotic plaques [35].
Using HUVECs, the effect of different types of LDL molecules
on the expression of endothelin system components have been
investigated [26]. Both nLDL and oxLDL increased ECE-1 mRNA
and protein expression within 1 and 24 h respectively, and re-
vealed a novel mechanism by which endothelial cells can regu-
late the expression of ECE-1 in response to circulating levels of
lipoproteins. The potential role of PKC and angiotensin II in lipo-
protein induced changes in ECE-1 expression has not been stud-
ies in the past. This study therefore investigated the effect of the
above mentioned lipoproteins on the expression of endothelin
system components in the presence of the non-isoform selective
PKC inhibitor, Ro-31-8220, and the angiotensin type II receptor
antagonist losartan [26]. Data presented indicate that nLDL in-
duced increase in ECE-1 expression was mediated through PKC
but not AT-II receptors. This was the reverse for the oxLDL in-
duced increase in ECE-1 expression [26]. Previous studies have
shown that ET-1 increases the formation of ROS in endothelial
cells [36]. This can increases the amount of oxLDL in the circu-
lation, which can in turn increase oxidative stress by itself. Fur-
thermore, ET-1 facilitates the uptake of oxLDL through the oxLDL
receptor LOX-1[37]. The discovery of LDL induced increase in
ECE-1 expression (and hence ET-1 production) completes a vi-
cious cycle of increased LDL levels, leading to increased ET-1
synthesis, ROS formation and hence modiﬁcation of nLDL to
oxLDL, ultimately leading to increased uptake of oxLDL by endo-
thelial cells [26] (Fig 3).
Although a study examining the combined effects of increased
laminar shear stress, and augmented levels of LDL on ECE-1
expression would parallel a clinical situation of hypertension and
hypercholesterolemia, such a study is yet to be undertaken. De-
tailed studies on this aspect should aim to identify not only the ef-
fect on ECE-1 expression, but the dominant cellular mechanism/stimuli at play which would ultimately govern the level and spe-
ciﬁc isoforms of ECE-1 expressed at the cell surface.
1.2.4. Statin therapy
A 2008 study by Goettsch et al. examined the ECE-1 mRNA lev-
els in the endothelial cells taken from arterial biopsies of patients
undergoing coronary artery bypass graft (CABG) [28]. ECE-1 levels
were compared across groups of patients receiving the following
types of pharmacological therapies: Angiotensin Converting En-
zyme Inhibitors (ACE-I), Angiotensin Receptor Blockers (ARB) and
HMG-CoA reductase inhibitors (Statins). Patients receiving statin
therapy showed signiﬁcantly higher levels of ECE-1 mRNA com-
pared to control patients who received a therapy not involving
the rennin–angiotensin system [28]. Analysis of isoform speciﬁc
mRNA indicated that statin induced increase in ECE-1 levels is lar-
gely due to the increase in mRNA corresponding to ECE-1a (main
isoform in endothelial cells) and ECE-1b [28]. Although it had no
overall effect on the total ECE-1 levels, ECE-1a mRNA levels were
signiﬁcantly higher in patients receiving ACE-I compared to ARB
therapy. This is the only study to take a post in vivo approach to
examine changes in ECE-1 levels in response to pharmacological
interventions. The authors only examined the total ECE-1 mRNA,
and as reported by the authors themselves the results should be
interpreted with caution due to the lower sample size used
(n = 4–9) [28]. Furthermore, this study fails to determine the effect
of these therapies on the expression of the speciﬁc ECE-1 isoforms
on the cell surface at the protein level. This again is largely due to
the lack of isoform speciﬁc antisera.
The authors also examined the effect of Ang II on the expression
of ECE-1 in primary human endothelial cells. In contrast to previ-
ous studies [26], Ang II failed to alter the mRNA levels of any
ECE-1 isoform compared to the time matched controls over the
course of 24 h. While this study only looked at the total mRNA
expression, it is possible that Ang II treatment may stimulate the
trafﬁcking of ECE-1 to the cell surface thereby increasing expres-
sion at the cell surface without stimulating the synthesis of
ECE-1 overall. Competitive RT-PCR analysis indicated that ECE-1a
isoform to be the most widely expressed, representing 60% of all
ECE-1 expression in HUVECs [28]. The relative abundance of each
speciﬁc ECE-1 isoform is currently a topic of debate with some
studies claiming ECE-1d to be the most abundant [38].
1.2.5. High glucose/diabetes
The link between vascular disease and diabetes is well estab-
lished and endothelins are at least partly responsible for the vascu-
lar complications of diabetes [39]. Hyperglycemia is the most likely
metabolic change to mediate an increase in ET-1 levels while
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els using endothelial cells show a time and concentration depen-
dant increase in ECE-1 expression in response to a high glucose
environment [18,25]. Five days of exposure to high levels of glu-
cose (22.2 mmol/l) increased ECE-1 expression on the surface of
Ea.hy926 cells by more than 20-fold compared to low levels of glu-
cose (5 mmol/l) [25]. Similar results were observed in relation to
primary HUVECs and this result was independent of NO levels [18].
Detailed studies on the mechanism behind increased ECE-1
expression indicated the involvement of PKC activation in this pro-
cess [18]. Increases in glucose concentration from 5 to 22.2 mmol/l
resulted in an increase in PKC activity of 72% & 41% in Ea.hy926
cells and HUVECs respectively [18]. Media containing high glucose
increased the activity of PKC isoforms b1, b2 and d by around 40%,
50% and 110% respectively, in Ea.hy926 cells compared to low glu-
cose medium [18]. High glucose environment had no effect on PKC
a expression, and the increased activity of other PKC isoforms in
response to high glucose were more pronounced in HUVECs. RT-
PCR conﬁrmed that only ECE-1c isoform expression increased in
response to high glucose in Ea.hy926 cells. These results were fur-
ther supported by immunoﬂuorescence studies which used iso-
form speciﬁc antisera, to demonstrate elevated levels of ECE-1c
at the cell surface in response to high glucose induced PKC activa-
tion [18]. The speciﬁc isoform of ECE-1 which increases in response
to high glucose in primary HUVECs however, was not determined.
Interestingly, increased expression of ECE-1a isoform in
Ea.hy926 cells, which is previously known to be mediated by
PMA induced PKC activation [14] was not detected in these studies.
This may reﬂect cellular processes other than PKC activation that
are likely to play a role in regulating the expression of speciﬁc
ECE-1 isoforms on the cell surface in a high glucose environment.
Follow up studies were conducted by the same group into the
mechanisms by which a high glucose environment increases
ECE-1 expression [25]. The glucose induced increase was indepen-
dent of osmolality as evidenced by studies using mannitol or
hypertonic saline. Increases in ECE-1 expression in response to
high glucose resulted in an increase in ET-1 secretion into media.
Normalisation of glucose levels in media fully reversed the ECE-1
expression levels within 48 h. The results from studies involving
isoform speciﬁc inhibitors of PKC such as Rottlerin (a PKC d inhib-
itor) and LY333351 (a PKC b inhibitor), together with studies in
which PKC isoforms were over expressed in HUVECs by adenoviral
transfection indicate PKC d isoform to be at least in part, responsi-
ble for high glucose induced increase in ECE-1 expression [25].
Other PKC isoforms had no effect on ECE-1 expression. A high glu-
cose environment increased PKC d isoform and ECE-1 expression
by 3-fold and 20-fold respectively. Transfection by adenoviral vec-
tor increased PKC d isoform expression by 17-fold which only re-
sulted in a 4.5-fold increase in ECE-1 expression [25]. Reasons
behind this discrepancy in expression levels are unknown.
According to studies conducted using CHO cells transfected
with ECE-1a and ECE-1b isoforms containing a GFP tag, PKC med-
iated phosphorylation stimulates the trafﬁcking of both isoforms to
the intracellular compartment [12] (Fig 2). This effect was also ob-
served when cells were incubated with media containing high glu-
cose (25 mM). However, the activation of PKA by forskolin (a PKA
activator) only resulted in the internalisation of ECE-1b. This is
consistent with the absence of PKA phosphorylation sites in ECE-
1a (Fig 2). There are no published studies which examine the traf-
ﬁcking of ECE-1a and b isoforms in endothelial cells. This study
only examined the effect of phosphorylation and glucose on the
expression/trafﬁcking of ECE-1a and b isoforms. Internalisation
may explain why only ECE-1c expression was detected in previous
studies using Ea.hy926 cells grown in a high glucose environment
[18]. Given that the cleavage of BigET by ECE-1 and the production
of ET-1 happen at the cell surface, the differential trafﬁcking ofeach ECE-1 isoform in response to high glucose may indicate differ-
ent functions for each isoform under hyperglycaemic conditions.
Although the production of ET-1 and hence vasoconstriction is
the main physiological role of ECE-1, recent research implicate
ECE-1 in a range of other physiological and pathophysiological pro-
cesses [4,41,42]. ECE-1 is one of the enzymes that degrade Ab40
peptide which contribute to the formation of Ab plaques, the hall
mark of Alzheimer’s disease (A) [8,43]. A recent study showed that
the over expression of PKCe in a transgenic mouse model of AD re-
sulted in a reduction in amyloid plaque levels [8]. This effect was
found to be mediated via an increase in ECE-1a expression. This
is the only study that provides clear evidence for the regulation
of ECE-1 activity via the PKCe isoform in addition to PKC d. The
authors fail to determine effect of increased PKCe expression on
ECE-1 phosphorylation and the precise ECE-1 isoform to be acti-
vated by PKCe in the brain. However the authors argue that in-
creased ECE-1 expression in Ea.hy926 cells is likely to be the
result of increased ECE-1a promoter activity (through transcription
factor Ets-1 binding) as shown by a previous study which used the
PKC activator PMA to demonstrate similar effects [14]. PKCe iso-
form however had no effect on the basal levels of ECE-1 expression.
Although further studies are needed to clarify, it is possible that
ECE-1c expression is regulated via PKC d mediated phosphoryla-
tion, while ECE1a expression is regulated by PKCe activation.
1.3. Herterodimerisation of ECE-1 isoforms
The ability of ECE-1 isoforms to form heterodimers can affect
their overall expression at the cell surface [44]. This was investi-
gated using the neuroendocrine cell line AtT-20 which is known
to also endogenously express ECE-1. Co-transfection of these cells
with FLAG tag containing ECE-1a and ECE-1b was followed by tri-
ple labelling experiments [44]. In addition to the formation of het-
erodimers, this study conﬁrmed the translocation of ECE-1a which
is mainly conﬁned to the plasma membrane into the cytosol. ECE-
1b isoform has intermediate distribution, and hetermodimerisa-
tion had no effect on its distribution. This suggests a dominant role
for the ECE-1b sorting signal(s), most likely the di-leucine motif
[44].
It has been proposed that the opposing effects of ECE-1a and
ECE-1c on the growth of prostate cancer cells is due to the possible
formation of heterodimers, leading to the abrogation of tumour
promoter effects of ECE-1c [22].
2. Conclusion
Expression and localisation of ECE-1 is an important factor
which governs the rate of ET-1 production. ET-1 has a variety of
functions including the regulation of vascular tone, hormonal func-
tion, foetal development and cancer progression. Hence research
on cellular pathways together with the identiﬁcation of external
stimuli which induce ECE-1 trafﬁcking may shed light on the po-
tential targets for the therapeutic manipulation of ECE-1 expres-
sion/localisation.
In vitro studies conducted using cell culture systems have thus
far identiﬁed phosphorylation to be the key process which indi-
rectly governs the cellular localisation and hence activity of ECE-
1. The effect of phosphorylation on the expression/localisation of
the individual ECE-1 isoforms has been restricted as a result of
the lack of isoform speciﬁc probes such as antibodies. Efforts have
been made to overcome this problem by analysing the mRNA lev-
els of the individual ECE-1 isoforms. This approach however fails to
conﬁrm the localisation of each isoform. Current research indicates
that phosphorylation induces the trafﬁcking of only ECE-1c isoform
to the cell surface, ECE-1a and 1b to the cytosol while there are no
published studies ECE-1d. Various stimuli including laminar shear
S. Kuruppu, A.I. Smith / FEBS Letters 586 (2012) 2212–2217 2217stress, hypercholesterolemia, ET-1 and various pharmacological
interventions have been examined for their effect on ECE-1 expres-
sion/localisation.
Further research should focus on validating the results of these
in vitro studies in an intact organism by taking a post in vivo ap-
proach. This will enable us to better understand the role of ECE-1
and its isoforms under physiological and pathological states. Such
studies will highlight the potential of therapeutically manipulating
ECE-1 expression and localisation for the treatment of several dis-
eases including cardiovascular disease and cancer in which ECE-1
plays an important role in the pathogenesis.
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